NRX Stock News 5.67 05/13/2014 11:36:02 Nephrogenex Inc. (NR

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nephrogenex Inc. (NRX) 5.67 $NRX

Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic

Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 01, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

NephroGenex, Inc. Reports Year-End 2013 Financial Results
GlobeNewswire - Mon Mar 31, 7:16AM CDT
-- Raised over $37 million in gross proceeds during Feb. 2014 Initial Public Offering

NephroGenex Announces Research Collaborations for Pivotal Studies of Pyridorin(TM) in Diabetic Nephropathy
GlobeNewswire - Thu Mar 27, 7:14AM CDT
NephroGenex, Inc.(Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced collaborations with two leading research organizations to conduct the Company's Phase 3 PIONEER (PyrIdOriN in DiabEtic NEphRopathy) study.

NephroGenex Announces Closing of Initial Public Offering
GlobeNewswire - Fri Feb 14, 10:30AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the closing of its initial public offering of 3,100,000 shares of common stock at a public offering price of $12.00 per share for total gross proceeds of $37,200,000 before underwriting discounts. In addition, NephroGenex has granted the underwriter a 45-day option to purchase up to an additional 465,000 shares of common stock from NephroGenex to cover over-allotments, if any.

NASDAQ Welcomes NephroGenex (NASDAQ:NRX) to The NASDAQ Stock Market
GlobeNewswire - Tue Feb 11, 11:24AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced that trading of NephroGenex (Nasdaq:NRX), a drug development company focusing on kidney disease, commenced on The NASDAQ Stock Market on February 11, 2014.

NephroGenex Prices Initial Public Offering of Common Stock
GlobeNewswire - Mon Feb 10, 5:49PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the pricing of its initial public offering of 3,100,000 shares of its common stock at an initial public offering price of $12.00 per share. The gross proceeds to NephroGenex is expected to be $37,200,000 before underwriting discounts and commissions and other offering expenses. All of the common stock is being offered by NephroGenex. In addition, NephroGenex has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of common stock from NephroGenex to cover over-allotments, if any. NephroGenex's common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading under the ticker symbol "NRX" on February 11, 2014.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 269

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 424

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 129

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 134

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 337

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 72

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 825

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 222

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Launch of Chuck's Arcade™ with Clawcade Experience

Updated Category News Views 270

Chuck E. Cheese Unveils Chuck's Arcade™ at Brea Mall Chuck E. Cheese is thrilled to announce the grand opening of its latest entertainment destination, the 10th Chuck's Arcade™, located at the Brea Mall. This unique arcade merges nostalgia with the excitement of claw machines, marking a fresh endeavor for a brand beloved by many. The Clawcade Experience Awaits...

Continue Reading
Apple's iPhone 17 Pro Could Feature Game-Changing Charging Tech

Updated Category News Views 351

Apple Revamps Charging with iPhone 17 Pro Apple Inc. (NASDAQ: AAPL) is on the brink of introducing an exciting feature in its upcoming iPhone 17 Pro: wireless reverse charging. This new capability may allow users to charge devices such as AirPods and the Apple Watch directly from their smartphone, offering unprecedented convenience. Unveiling the Features Recent reports,...

Continue Reading
Wiki Wiki Shuttle Electrification: Game Changer or Just Hype?

Updated Category News Views 134

February 17, 2026, marks a pivotal moment as the Wiki Wiki Shuttle at Daniel K. Inouye International Airport (HNL) just rolled out three shiny new electric transit trams under a state electrification contract. Yeah, you heard that right—Sustainability Partners delivered these MotoEV Electro Transit Buddy trams to pump up the airport's low-emission transport game. But...

Continue Reading
Canada's Science Literacy Week 2025: A Celebration of STEM Education

Updated Category News Views 232

United for Science Literacy Week 2025 OTTAWA, Ontario – The Canadian Association of Science Centres (CASC) is gearing up for a national celebration as educators and leaders in STEM come together for Science Literacy Week. This initiative aims to ignite curiosity and deepen engagement in science across Canada, promoting the importance of STEM education. Igniting...

Continue Reading
Quipt Home Medical Starts Joint Venture with Major Health Systems

Updated Category News Views 235

Quipt Home Medical Forms Joint Venture with Esteemed Health Systems In a groundbreaking move, Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT), a prominent player in the home medical equipment market, has officially entered into an agreement with three major health systems to establish a strategic joint venture. This definitive agreement allows Quipt to acquire a 60%...

Continue Reading